It’s imperative to devote more resources to infectious-disease control, leading to the development of new antibiotics. In 2015, the U.S. White House launched a national action plan against antimicrobial resistance (AMR), also commonly known as antibiotic resistance. In 2017, the World Health Organization (WHO) announced the 12 types of highly resistant bacteria that pose the…

If you’ve taken any medicine lately in the Asia-Pacific region, it’s highly likely that Zuellig Pharma delivered it to your healthcare provider or pharmacy. Distributing pharmaceuticals is a complex business involving cold-chain management and other massive logistical challenges that most of us take for granted. The company’s mission is to make healthcare more accessible to…

The Novartis motto – “Reimagining Medicine” – goes to the heart of the company’s deep commitment to developing innovative drugs to help fill the unmet needs of patients worldwide. The Swiss-based pharmaceutical multinational consistently ranks among the top companies investing in R&D, ensuring a constant pipeline of new and groundbreaking treatments. In 2017 the investment…

In recent years the utilization of risk-sharing mechanisms – also known as managed entry agreements (MEAs) – has become increasingly common in healthcare systems around the world. Britain, Italy, Canada, and Korea are prominent examples. These arrangements have been welcomed by both the pharmaceutical industry and national healthcare administrations as a means of accommodating innovative…

Transforming Taiwan into a regional biomedical hub will require some creativity. Taiwan’s biomedicine industry has many of the ingredients for success. The island has strong scientific talent, rich clinical-trial experience, abundant capital, a treasure trove of medical data (from the National Health Insurance system), information-technology expertise, and strong intellectual property rights protection bolstered by the…